Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company''s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest shares articles
GBP/USD attempts recovery as UK CPI rises once again
UK inflation rose unexpectedly in June, moving further away from the Bank of England's 2% and limiting the amount of future rate cuts
08:25, 16 July 2025
EUR/USD: bullish narrative tested by U.S. trade threats
US tariff threats weigh on euro sentiment as the dollar regains the upper hand
07:47, 15 July 2025
US CPI Preview: Inflation data to test Fed’s tariff assumptions and policy expectations
US CPI data could impact the Fed's views on tariffs, inflation and monetary policy
18:52, 14 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:59, 14 July 2025
Ratings and Reviews
Ratings and Reviews
